Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456243 · ClinicalTrials.gov registry record · Phase 1
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
A Phase 1 study of Kidney Transplant, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05456243: Recruiting Phase 1 study of Kidney Transplant, sponsored by Mayo Clinic.
NCT05456243 is a Phase 1 study of Kidney Transplant that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 12 participants, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05456243, a Phase 1 study of Kidney Transplant, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.
Primary Outcome
Number of subjects to have biopsy-proven worsening kidney allograft rejection
Conditions Studied
Interventions
- BIOLOGICAL Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- BIOLOGICAL High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What NCT05456243 shows while recruiting
NCT05456243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,898-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Low dose adipose tissue derived mesenchymal stromal cells (A-MSC) is the first listed.
NCT05456243 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05456243 about?
NCT05456243 is a clinical study titled "Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients". This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.
What is the current status of trial NCT05456243?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-01-30. Estimated completion is 2026-04.
What conditions does trial NCT05456243 study?
This clinical trial studies the following conditions: Kidney Transplant.
What interventions are being tested in trial NCT05456243?
The interventions under investigation include: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC) (BIOLOGICAL), High dose adipose tissue derived mesenchymal stromal cells (A-MSC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05456243?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05456243 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05456243's enrollment target sits among peer trials
12 28th of 30 higher than 3 of 30 other Kidney Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
RECRUITING · Phase 1
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
ACTIVE NOT RECRUITING · Phase 1
-
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI